Khang & Khang LLP (the "Firm") announces a class action lawsuit against Impax Laboratories Inc. ("Impax" or the "Company") (Nasdaq: IPXL). Investors, who purchased or otherwise acquired shares between February 25, 2014 and November 3, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the January 9, 2017 lead plaintiff motion deadline. If you purchased shares of Impax during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org. There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. The complaint alleges that Impax made false and/or misleading statements and/or failed to disclose: that the Company was engaged in conduct that would trigger investigations of possible collusion of generic drug pricing by the antitrust division of the U.S. Department of Justice ("DOJ") and the Connecticut Attorney General; that the DOJ investigation and the underlying conduct would likely result in criminal charges against Impax for collusion of generic drug pricing; that the Company lacked effective internal controls over financial reporting; and that as a result of the above, Impax's public statements were materially false and misleading at all relevant times. When this information was disclosed, shares of Impax declined in value, which caused investors harm.